Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe data on the relationship between baseline HIV-1 RNA and virologic response rates in patients receiving abacavir/lamivudine in several recent trials
- Discuss the impact of baseline resistance to etravirine and/or darunavir on virologic response rates in patients in the DUET trials
- Summarize recent findings on the impact of switching enfuvirtide to raltegravir in virologically suppressed patients
- Restate the results of several recent analyses of the association between abacavir use and cardiovascular risk
- Outline patterns of virologic response and adverse events by patient sex and patient race in several recent clinical studies
CCO Expert Recaps combine slides with audio commentary by our esteemed faculty. Complete the CME posttest and evaluation after watching the presentation.